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Purpose. The pathogenesis of rhegmatogenous retinal detachment (RRD) remains incompletely understood, with no clinically
effective treatment for potentially severe complications such as photoreceptor cell death and proliferative vitreoretinopathy. Here
we investigate the protein profile of the vitreous following experimental retinal detachment using a comparative proteomic based
approach.Materials andMethods. Retinal detachment was created in the right eyes of six NewZealand red pigmented rabbits. Sham
surgery was undertaken in five other rabbits that were used as controls. After seven days the eyes were enucleated and the vitreous
was removed. The vitreous samples were evaluated with two-dimensional polyacrylamide gel electrophoresis and the differentially
expressed proteins were identified with tandem mass spectrometry. Results. Ten protein spots were found to be at least twofold
differentially expressed when comparing the vitreous samples of the sham and retinal detachment surgery groups. Protein spots
that were upregulated in the vitreous following retinal detachment were identified as albumin fragments, and those downregulated
were found to be peroxiredoxin 2, collagen-I𝛼1 fragment, and 𝛼-1-antiproteinase F. Conclusions. Proteomic investigation of the
rabbit vitreous has identified a set of proteins that help further our understanding of the pathogenesis of rhegmatogenous retinal
detachment and its complications.
1. Introduction
Rhegmatogenous retinal detachment (RRD) is characterized
by the accumulation of subretinal fluid between the neuro-
sensory retina and retinal pigment epithelium following the
formation of a retinal break [1]. The pathogenesis of RRD is
complex and incompletely understood, involving age-related
and/or inherited structural and molecular changes of the
vitreous extracellular matrix and vitreoretinal interface, and
the process of posterior vitreous detachment [2]. The annual
incidence of the condition has been estimated at 12.05 per
100,000, and although primary surgical reattachment is suc-
cessful in the greatmajority of cases, photoreceptor cell death,
subretinal fibrosis, and proliferative vitreoretinopathy (PVR)
continue to be significant causes of reduced visual outcomes
[3, 4].
PVR involves the proliferation and migration of various
cell types including retinal pigment epithelial (RPE) cells,
Mu¨ller cells, inflammatory cells, and hyalocytes, which con-
tribute to the formation of vitreal and periretinal membranes
that can impede photoreceptor regeneration following surgi-
cal reattachment and cause tractional retinal detachment.The
postulated epithelial-to-mesenchymal transition of RPE cells
and Mu¨ller cell activation and growth onto the retinal sur-
faces are believed to be pivotal events in PVR [4, 5]. It appears
that the exposure of such cells to the vitreous and associated
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growth factors as a result of RRD significantly contributes to
the pathogenesis of PVR, though the basic cause as well as
a clinically effective therapeutic approach for this condition
remains elusive [5, 6].
Proteomics studies proteins on a large scale in pursuit of a
global and integrated view of disease processes at the protein
level, whichmay potentially lead to the identification of novel
biomarkers and therapeutic targets useful in clinical practice
[7–11]. RRD would likely be associated with alterations in the
proteomic profiles of both the retina and vitreous. Indeed, we
initially undertook the first such retinal study from which a
number of potentially important proteinswere identified [12].
The present study extends the proteomic investigation to the
vitreous of this rabbit model of retinal detachment, building
upon previous such analyses of human vitreous [13–16], in
order to add further knowledge of the underlying pathophys-
iology [10, 17].
2. Materials and Methods
2.1. Retinal Detachment Surgery. Inferior retinal detachment
was created in the right eyes of six New Zealand red pig-
mented rabbits. The eyes were normal with no evidence of
disease on examination. Combined injections of xylazine
(6.7mg/kg) and ketamine (33.3mg/kg) were administered
intramuscularly to induce anesthesia and analgesia. The
pupils were dilatedwith topical drops of atropine and tropica-
mide (1% solutions). A pipette tip, with an external diameter
of approximately 100 𝜇m, was inserted into the eye through
a pars plana incision. Sodium hyaluronate (Healon, 0.25%
in a balanced salt solution; Pharmacia, Piscataway, NJ) was
infused via a glass pipette between the neurosensory retina
and retinal pigment epithelium.Healon was necessary to pre-
vent spontaneous retinal reattachment, and 0.25% is themost
dilute solution that maintains the detachment for extended
periods. Approximately 50% of the retina beneath themedul-
lary rays, which included the central retina, was detached
(Figure 1). Sham surgery was performed in the right eyes of
five other rabbits that were used as controls, which involved
surgical entry of the vitreous cavity without disruption of the
retina. Scleral incisions were closed with 8-0 nylon suture.
Seven days postoperatively the animals were euthanized
by the administration of sodium pentobarbital (120mg/kg;
Butler Schein, Dublin, OH) and the eyes enucleated. After
removal of the cornea and lens, the associated vitreous of the
sham and detached retinas was extracted and immediately
snap-frozen in liquid nitrogen within separate vials. There
was no gross evidence of blood or other contamination of
the vitreous samples at the time of tissue harvesting. The
vitreous samples were stored at −80∘C until further use.
All of the animal experiments undertaken in this study
were in accordance with the standards of the National Insti-
tutes of Health Animal Care and Use Committee protocols,
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research, and the guidelines of the Animal
Resource Center, University of California, Santa Barbara.
2.2. Protein Extraction. The rabbit vitreous samples were
homogenized and dissolved in a lysis buffer containing 9M
Figure 1: Appearance of the retinal detachment in the rabbit eye at
seven days. The area of detached retina beneath the medullary rays
appears grey and is surrounded by the darker attached retina. The
detached retina contains a small hole where the micropipette was
inserted. The retinal folds in the periphery occurred during the
removal of the anterior structures.
urea, 2% (v/v) Triton X-100, 2% (v/v) immobilized pH gradi-
ent (IPG) buffer (pH 3–10 nonlinear), and 2% (w/v) dithio-
threitol (DTT). The total protein content in each vitreous
sample was determined with Non-Interfering Protein Assay
(Calbiochem, San Diego, CA). The protein samples were
stored at −80∘C until further use.
2.3. Two-Dimensional Gel Electrophoresis. The extracted
proteins were first fractionated by isoelectric focusing (IEF)
using pH 3–10 nonlinear 18 cm IPG strips (GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK). The IPG strips
were rehydrated for 20 h at room temperature in 200 𝜇L lysis
buffer each containing 20 𝜇g protein from individual vitreous
samples and 150 𝜇L rehydration buffer (8M urea, 2% (w/v)
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfo-
nate (CHAPS), 0.3% (w/v) DTT, and 2% (v/v) IPG buffer),
using the Immobiline DryStrip Reswelling Tray (GE Health-
care).The IEF was undertaken on aMultiphor II Electropho-
resis System (GE Healthcare) at 500V for 5 h and 3500V
in two steps for 5 h and 9.5 h in a gradient mode at 17∘C
with the use of a MultiTemp III Thermostatic Circulator (GE
Healthcare). Before the second-dimension sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE),
the IPG strips were equilibrated firstly for 10min with gentle
agitation in 20mL of equilibration solution (0.6% (w/v) Tris-
HCl, pH 6.8, 6M urea, 30% (v/v) glycerol, 1% (w/v) SDS, and
0.05% (w/v) DTT) and secondly using 4.5% (w/v) iodoaceta-
mide and bromophenol blue. The IPG strips were then
transferred to 12% polyacrylamide gels for electrophoresis,
which was performed at a maximum voltage of 50V for
approximately 20 h to separate the proteins vertically on the
basis of molecular mass.
2.4. Protein Staining. Thetwo-dimensional (2D) gelswere sil-
ver stained using a protocol optimized for protein identifica-
tion with mass spectrometry [18]. In brief, the gels were fixed
overnight in 50% (v/v) ethanol, 12% (v/v) acetic acid, and
0.0185% (v/v) formaldehyde. The gels were washed 3 times
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for 20min in 35% (v/v) ethanol and pretreated for 1min
in 0.02% (w/v) Na
2
S
2
O
3
⋅5H
2
O. They were then rinsed
in water and stained for 20min in 0.2% (w/v) AgNO
3
and 0.028% (v/v) formaldehyde. Following further rinsing
with water, development was undertaken for approximately
3min in 6% (w/v) Na
2
CO
3
, 0.0185% (v/v) formaldehyde, and
0.0004% (w/v)Na
2
S
2
O
3
⋅5H
2
O.Thedevelopmentwas arrested
in a fixative solution of 40% (v/v) ethanol and 12% (v/v) acetic
acid. The 2D gels were then dried between cellophane sheets
and sealed in plastic envelopes.
2.5. Image Analysis. Silver stained 2D gels were scanned on
a GS-710 Calibrated Imaging Densitometer (Bio-Rad, Her-
cules, CA) using the Quantity One program (Bio-Rad), and
the PDQuest software (Bio-Rad) was used to define, quantify,
and match the protein spots on each of the 2D gels. All
well-defined protein spots that were at least twofold (Mann-
Whitney 𝑈 test, 𝑝 < 0.05) differentially expressed between
the sham and retinal detachment vitreous groups were
selected for identification with nanoliquid chromatography-
electrospray ionization tandem mass spectrometry (LC-
MS/MS).
2.6. Protein Identification. The 2D gels were removed from
their plastic envelopes and rehydrated in water. The selected
protein spots were carefully excised from the gels with a
scalpel and subjected to in-gel digestion with Trypsin Gold
(Mass Spectrometry Grade; Promega, Madison, WI). The
peptide samples that were obtained were analyzed by LC-
MS/MS as previously described [12]. In brief, peptides gen-
erated by trypsin digestion were separated on an inert nano-
LC system (LC Packings, San Francisco, CA) connected to a
Q-TOF Premier mass spectrometer (Waters, Milford, MA).
TheMassLynx 4 SP4 (Waters) was used to obtain spectra and
the raw data was processed using ProteinLynx Global Server
2.1 (Waters). The processed data were used to search the total
part of the Swiss-Prot database using the online version of
theMascotMS/MS Ions Search facility (Matrix Science, Ltd.).
The search was undertaken with doubly and triply charged
ions with up to two missed cleavages, a peptide tolerance
of 50 ppm, one variable modification, carbamidomethyl-C,
and a MS/MS tolerance of 0.05Da. Contaminating peptides
such as trypsin, keratin, bovine serum albumin, and all
peptides originating fromprevious sampleswere disregarded.
At least one “bold red” (Matrix Science Ltd., http://www
.matrixscience.com/) peptide match was required in the
search for protein hits. Individual peptide ions scores above
approximately 36 indicated identity or extensive homology
giving a less than 5% probability that the observed match was
a random event. All peptides for the protein hits are reported
(Table 1).
2.7. Western Blotting. In each case three micrograms of vitre-
ous sample protein was separated on Novex 10–20% gradient
Tris-Glycine polyacrylamide gels (Invitrogen Corporation,
Carlsbad, CA) and subsequently transferred to nitrocellulose
Hybond-C Extra membranes (GE Healthcare). The mem-
branes were blocked overnight with 5% skimmed milk in
80mM Na
2
HPO
4
, 20mM NaH
2
PO
4
, 100mM NaCl, and
0.05% Tween 20 buffer, pH 7.5. Membranes were incubated
with anti-albumin (Genway Biotech, CA, USA; 1 : 5000) and
anti-peroxiredoxin 2 (Abcam, Cambridge, UK; 1 : 200). No
suitable antibodies were commercially available for the rabbit
F isoform of 𝛼-1-antiproteinase or the rabbit collagen-I𝛼1
fragment that was identified with LC-MS/MS. Following
washing, the membranes were further incubated with appro-
priate horseradish peroxidase-conjugated secondary anti-
bodies: P0163 sheep and P0260 mouse (both 1 : 1000; DAKO,
Glostrup, Denmark). Proteins were visualized with the enha-
nced chemiluminescence system (GE Healthcare) and imag-
ing system (Fujifilm LAS-3000, Tokyo, Japan).
3. Results
3.1. 2D-PAGE Analysis. Up to approximately 340 protein
spots were clearly resolved on each of the 11 2D gels. Ten pro-
tein spots were found to be significantly and at least twofold
differentially expressed between the sham and detachment
vitreous groups (Figure 2). Three protein spots were upreg-
ulated and seven spots were downregulated.
3.2. LC-MS/MSAnalysis. From the three upregulated protein
spots, two were identified as fragments of albumin (spots
5104 and 6101), whilst spot 6205 could not be identified.
Four of the seven downregulated protein spotswere identified
as fragment of collagen-I𝛼1 (spot 0503), 𝛼-1-antiproteinase
F (spots 0703 and 1707), and peroxiredoxin 2 (spot 0705).
Protein spots 0102, 0815, and 1302 could not be identified
(Figure 2; Table 1).
3.3. Western Blot Analysis. Western blotting developed with
anti-albumin showed a heavy band at approximately 60 kDa,
which is likely to represent the full length protein, whilst
multiple bands below this suggest the presence of several
fragments, some of which may correspond with those identi-
fiedwith the 2D-PAGE analysis (Figure 3, left). Peroxiredoxin
2 has a deduced molecular mass of approximately 22 kDa.
However, spot 0705 containing peroxiredoxin 2migrateswith
a molecular mass around 60 kDa with 2D-PAGE (Figure 2),
and this size was verified by western blot analysis (Figure 3,
right). Though a single and specific band was achieved with
anti-peroxiredoxin 2, western blotting could not be reliably
used for quantification due to aweak signal near the detection
limit and variable background reaction.
4. Discussion
4.1. Albumin. Analysis with 2D-PAGE revealed fragments
of albumin to be upregulated in the vitreous following reti-
nal detachment. Albumin is the most abundant protein in
plasma, aqueous, and vitreous humor, where in the latter it
constitutes around 60–70% of total protein [19–21]. Serum
proteins such as albumin are present in the aqueous and vitre-
ous humor at a relatively lower level compared to the vascular
circulation from where they may have in part originated [21,
22]. Western blot analysis showed an intense band at approx-
imately 60 kDa corresponding with the full length albumin
4 Journal of Ophthalmology
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Figure 2: Representative 2D-PAGE images of proteins fractionated from rabbit vitreous. Ten protein spots (arrows) were found to be
significantly and at least twofold differentially expressed between the sham (a) and detached (b) vitreous.
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Figure 3: Western blot analysis of sham rabbit vitreous developed
with anti-albumin and anti-peroxiredoxin 2. Labeled arrows corre-
spond to the respective full length proteins. The unlabeled arrows
for the lower molecular mass bands on the anti-albumin blot may
indicate the specific cleavage fragments, which correspond with
some of the differentially expressed 2D-PAGE protein spots.
protein, with multiple lower molecular mass bands that are
likely its fragments. Increase of albumin and its fragments
may signify increased proteolysis and the passage of albumin
into the vitreous. Indeed, the breakdown of the blood-retinal
barrier that occurs with retinal detachment has also been
implicated in the increase of other such proteins in the vitre-
ous [12, 23–28]. It is also possible that albumin in the vitreous
may arise from de novo synthesis in the retina, similar to the
reported increased gene and protein expression of albumin in
the corneal epithelium during wound healing [29, 30].
Extraocular albumin is known to have diverse and impor-
tant functions, which includemaintenance of colloid osmotic
pressure, transport of biomolecules, and inactivation of tox-
ins through intermolecular binding [31, 32]. Albumin can also
act as an antioxidant by scavenging reactive oxygen species
and sequestration of metal ions and has anti-inflammatory
and apoptotic regulatory abilities [32–35]. Vitreal albumin
has been proposed to transport long chain fatty acids into the
lens for biosynthesis of lenticular lipids [21, 31, 36]. Indeed,
albumin is likely to have many such important roles in the
eye, which requires further investigation.
4.2. Peroxiredoxin 2. In the present study we observed perox-
iredoxin 2 to have a molecular mass above 60 kDa using both
2D-PAGE and western blot analyses. However, the predicted
molecular mass of the peroxiredoxin family of proteins is
approximately 22 kDa–31 kDa. This variation may represent
the well-studied property of these proteins to undergo
oligomerization, which can be promoted by a number of fac-
tors including overoxidation of cysteine residues of perox-
iredoxin [37]. Although the present experiments were con-
ducted in standard reducing conditions that aim to break
cysteine bonds, we obtained a band well above 20 kDa.This is
in keeping with another study, which also showed some per-
oxiredoxin 2 western blot bands appearing at molecular mass
much higher than 20 kDa that was suggested to result from
oligomerization or posttranslational modification [38]. Our
finding could also represent a novel alternative splicing vari-
ant of peroxiredoxin 2, as reported for peroxiredoxin 5 [39].
The peroxiredoxins are a group of ubiquitous antioxidant
proteins that currently comprise six members in mammals
[40]. These proteins are primarily found at high levels intra-
cellularly, mainly within the cytosol, but are also present in
the mitochondria, peroxisomes, and nuclei, and they may be
exported [37]. Furthermore, presence of peroxiredoxin 2 has
been shown in plasma, not only as a result of hemolysis but
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also possibly by secretion from the T lymphocytes [41, 42].
These multifunction enzymes act as antioxidants by using
redox active cysteines for the reduction and degradation of
hydrogen peroxide, peroxynitrite, and organic hydroperox-
ides [37, 43]. Oxidative stress is thought to result from an
imbalance between reactive oxygen species production and
antioxidant ability and is recognized to be an important factor
in the pathogenesis of a number of age-related and neurode-
generative diseases, which include age-related cataract, age-
related macular degeneration, glaucoma, diabetic retinopa-
thy, retinal detachment, and PVR [44–47]. Indeed, the
present study showed a decrease in the vitreal levels of
peroxiredoxin 2 following retinal detachment.This may be in
keeping with reported reductions in the levels of other mem-
bers of the antioxidant defense system such as glutathione
and ascorbic acid both in vitreal and in blood samples of
patients suffering from PVR [44, 45]. Furthermore, apart
from their role as antioxidants, the peroxiredoxins can affect
a diverse range of biological processes that include cellular
proliferation, differentiation, and apoptosis by influencing
signal transduction pathways that employ hydrogen peroxide
as a secondary messenger [43, 48]. Recent studies on tears
from patients with glaucoma have also identified peroxire-
doxin 1 as having a possible involvement in inflammation
[49, 50]. Indeed, peroxiredoxin 2 and other members of this
family of proteins are liable to have a significant role in the
pathophysiology of retinal detachment.
4.3. Collagen-I𝛼1. A fragment of collagen-I𝛼1 was identified
in the vitreous of the rabbit; however, type I collagen has
not previously been identified as a natural component of the
mammalian vitreous and is rather known to be a constituent
of early PVR membranes [51–53] and retinal blood vessels
[54, 55]. A mixture of type II, IX, and V/XI hybrid collagen
fibrils, which are separated out mainly by water and ions
attracted to hyaluronan, characterizes the vitreous body [56].
Collagen, possibly with the aid of adhesive-like intermediate
molecules, may provide the basis of vitreoretinal adhesion
by connecting the vitreous with the retinal inner limiting
membrane (ILM). This attachment is extremely strong in the
vitreous base since the fibrils pass through the ILM to merge
into underlying collagen networks and crypts [2, 56, 57].
Collagen is also a significant component of both epiretinal
and subretinal PVR membranes [53, 58], and type I collagen
is recognized to be a principal constituent during their early
development [51–53].The presence of collagen in the subreti-
nal space, a place normally devoid of this protein, suggests
that certain cells, particularly the RPE and Mu¨ller cells asso-
ciated with membranes, are able to synthesize collagen under
certain pathological conditions such as retinal detachment
and PVR [58–61]. However, the present analysis suggests
collagen-I𝛼1 fragment to be found in sham vitreous, which
furthermore showed a decreased concentration following
retinal detachment that may indicate perturbed proteolytic
activity. Matrix metalloproteinases (MMP) and other prote-
olytic enzymes that are able to degrade and remodel vitreal
collagen have been found to be increased with RRD and
PVR [62–65], which could be in keeping with the decrease
in 𝛼-1-antiproteinase shown in the present study. Further
studies will be necessary to confirm the source and nature of
collagen-I𝛼1 in the vitreous and the possible mechanisms of
collagen fragmentation that may be an important feature of
vitreous liquefaction and RRD [2, 62, 66].
4.4. Alpha-1-Antiproteinase. 2D-PAGE showed 𝛼-1-antipro-
teinase (also called 𝛼-1-antitrypsin or 𝛼-1-proteinase inhibi-
tor) at two closely positioned spots, which were largely in
keeping with their predicted molecular mass but differing by
their charge. Currently, four isoforms of 𝛼-1-antiproteinase
have been identified in the rabbit, termed F, S1, S2, and E,
which is a similar picture to the multiple variants identified
in humans [67, 68]. Alpha-1-antiproteinase is an acute phase
protein and archetypal member of the superfamily of serine
protease inhibitors (serpin), which are involved in a wide
range of biological processes that includes inflammation,
angiogenesis, blood coagulation, ECM remodeling, and
tumor suppression [69].This protein has the ability to inhibit
a large number of serine proteases though its principle target
is neutrophil elastase [68]. Indeed, 𝛼-1-antiproteinase origi-
nally receivedmuch attention because its deficiency increases
the risk of a variety of clinical conditions, such as chronic
obstructive pulmonary disease, which can result from unre-
strained elastase activity.
We found the F isoform of rabbit 𝛼-1-antiproteinase to be
downregulated in the vitreous following retinal detachment.
The F isoform of 𝛼-1-antiproteinase is the only one of the
rabbit isoforms so far identified that has been shown to
have the oxidizable methionine residue site that is present in
human 𝛼-1-antiproteinase [67]. The oxidation of methionine
to methionine sulfoxide, which can occur during episodes of
inflammation as a result of oxygen-free radicals secreted by
leucocytes, has an inhibiting effect upon 𝛼-1-antiproteinase
function.This process is thought to enhance the ability of pro-
teinases such as elastase to locally degrade tissue debris that
occurs at sites of inflammation [67, 68].
Alpha-1-antiproteinase is primarily produced in the liver
and circulated to the rest of the body tissues via the blood;
however, extrahepatic sites of its synthesis have been identi-
fied, which include blood monocytes, alveolar macrophages,
bronchial and gastrointestinal epithelial cells, and the cornea
[70–73]. The protein has also been localized to the tear film,
aqueous humor, and vitreous, where in the latter a phospho-
rylated form of 𝛼-1-antiproteinase has been suggested as a
potential biomarker of idiopathic macular hole and rhegma-
togenous retinal detachment [73–75]. It has been postulated
that one of themain functions of corneal𝛼-1-antiproteinase is
to protect against the damaging effects of neutrophil elastase
produced during corneal inflammation [73], and it may be
expected that a similar role in addition to others is applicable
to vitreal 𝛼-1-antiproteinase, though this requires further
investigation.
5. Conclusion
This proteomic investigation of the rabbit vitreous has iden-
tified a set of proteins that assist our understanding of the
pathogenesis of rhegmatogenous retinal detachment and its
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complications. Further studies will be necessary to clarify the
role of these proteins. Certain proteins, such as those of low
abundance and at the extremes of molecular mass, together
with membrane proteins, can be difficult to resolve and
detect using the 2D-PAGE technique.Therefore, complemen-
tary proteomic methods such as gel-free mass spectrometry
should be considered in future work in order to help address
these limitations.
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